NEW YORK, NY / ACCESSWIRE / August 22, 2018 / U.S. markets continue to edge higher on Tuesday as optimism over trade talks and upbeat earnings pushed equities into the green. Additionally, the Federal Reserve will release details on the latest meeting on Wednesday. On Friday, Fed Chairman Jerome Powell is scheduled for a speech at the Kansas City Fed’s annual summer retreat. The Dow Jones Industrial Average hiked 0.25 percent to close at 25,822.29, while the S&P 500 Index have gained 0.21 percent to close at 2,862.96. The Nasdaq Composite Index increased 0.49 percent to close at 7,859.17.
Investment strategist at Edward Jones, Kate Warne said, “I think that this is optimism on at least some partial resolution of the trade negotiations as investors are expecting progress [on that front].” “If we reach new highs that’s great but I think it would be a reflection of the positive underlying fundamentals of very positive earnings growth and modest interest rates,” Warne added.
RDI Initiates Coverage on:
Sage Therapeutics, Inc.
Sage Therapeutics' stock jumped 3.8% Tuesday, to close the day at $153.87. The stock recorded a trading volume of 357,369 shares, which was below its three months average volume of 520,067 shares. In the last year, Sage Therapeutics' shares have traded in a range of 59.57 - 195.97. The share price has gained 158.3% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $156.04 is below its 200-day moving average of $159.51. Shares of Sage Therapeutics have fallen roughly 8.71 percent in the past month and are down 6.58 percent year-to-date.
Access RDI's Sage Therapeutics, Inc. Research Report at:
On Tuesday, shares of CEL-SCI recorded a trading volume of 2,348,606 shares, which was above the three months average volume of 620,628 shares. The stock ended the day 35.59% higher at $1.60. The share price has fallen 56.28% from its 52-week high with a 52-week trading range of 0.82 - 3.66. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.94 is below its 200-day moving average of $1.88. Shares of CEL-SCI have gained roughly 84.09 percent in the past month and are down 14.29 percent year-to-date.
Access RDI's CEL-SCI Corporation Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.